乳腺癌组织中pparγ与内分泌治疗预测指标相关性.docVIP

乳腺癌组织中PPARγ与内分泌治疗预测指标相关性 【摘要】nbsp; ［目的］ 研究乳腺癌组织中过氧化物酶增殖激活受体γ( peroxisome proliferator activated receptors γ ,PPARγ )的表达与 ER、PR、pS2、C-erbB-2 之间的关系，探讨其临床意义。［方法］应用组织芯片和免疫组织化学EnVision 法检测 71 例乳腺癌组织和 41 例非癌组织 PPARγ、 ER、PR、pS2、C-erbB-2的表达。［结果］ （1）71 例乳腺癌中 PPARγ、ER、PR、pS2 和C-erbB-2的阳性表达率分别为 47.89％、64.79％、61.97％、39.44％ 和 40.85％。（2）PPARγ 的表达与组织学分级呈正相关（Plt;0.01）。（3）PPARγ 的表达与 ER、PR表达分别呈正相关(C1=0.3102，C2＝0.2441)，与pS2、C-erbB-2的表达无显著性相关(Pgt;0.05 )。［结论］ PPARγ在分化较好和 ER阳性乳腺癌中高表达，与 ER、PR、pS2、C-erbB-2联合检测有助于指导内分泌治疗及评估预后。 【关键词】nbsp; 乳腺肿瘤 nbsp;nbsp;nbsp; Correlation betweennbsp; PPARγ and the Predictors of Endocrinotherapynbsp; in Breast Cancer Tissue nbsp;nbsp;nbsp; Abstract: ［Purpose］ To investigate expression of peroxisome proliferator activated receptors γ (PPARγ) in breast cancer and to explore their significance and relationships with estrogen receptors(ER), progesteron receptors(PR), pS2 and C-erbB-2. ［Methods］ The expressions of PPARγ, ER, PR, pS2 and C-erbB-2 in tissues of 71 cases with breast cancer and non cancer tissues of 41 cases were detected by microarray and immunohistochemistry with EnVision methods. ［Results］ (1) The positive rates of PPARγ, ER, PR, pS2 and C-erbB-2 in 71 cases with breast cancer were 47.89%, 64.79%, 61.97%, 39.44% and 40.85% respectively.（2）The expression of PPARγ was negatively correlated to histopathological grade (Plt;0.01 ). （3）The expression of PPARγ was positively correlated to ER and PR (C1=0.3102，C2＝0.2441 ), but was not statistically correlated with pS2 and C-erbB-2 (Pgt;0.05). ［Conclusions］ PPARγ is overexpressed in well-differentiated and ER-positive breast cancer. Combination examination of PPAR, ER, PR,pS2 and C-erbB-2 may be helpful for guiding endocrinotherapy and evaluating prognosis. nbsp;nbsp;nbsp; Key words: breast neoplasms; peroxisome proliferator activated receptorsγ; ER;PR; C-erbB-2 nbsp;nbsp;nbsp; 乳腺癌是一种激素依赖性全身性疾病，不同激素受体状态的乳腺癌患者在内分泌治疗反应性和预后方面存在明显差异。研究发现，ER-α作为乳腺癌内分泌治疗的金标准，在判断预后和激素治疗效果上并不完美。许